Kidney function and the effectiveness and safety of direct oral anticoagulants in atrial fibrillation: the KODIAK-AF study [ 2018 - 2019 ]

Research Grant

[Cite as]

Researchers: A/Pr Martin Gallagher (Principal investigator) ,  A/Pr Meg Jardine Dr Min Jun

Brief description The direct oral anticoagulants (DOACs) are a relatively new type of drug that are used to prevent the onset of stroke among patients with atrial fibrillation (AF). While these drugs have been demonstrated to be safe and effective among AF patients, in those AF patients with chronic kidney disease (CKD), there is uncertainty as to whether these drugs are similarly safe. This program of research will study the safety profile of DOACs in patients with AF and CKD.

Funding Amount $AUD 451,730.41

Funding Scheme Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]